{"id":"eritoran","rwe":[{"pmid":"41869302","year":"2026","title":"Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41369124","year":"2026","title":"The Therapeutic Targeting Effect of Toll-Like Receptors and Their Related Signaling Pathways in Cardiomyopathy.","finding":"","journal":"Immunological investigations","studyType":"Clinical Study"},{"pmid":"41097347","year":"2025","title":"Synthesis and Docking Studies of Glycolipids Inspired by Bacteroides fragilis Lipid A.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40128912","year":"2025","title":"Dietary emulsifier carboxymethylcellulose-induced gut dysbiosis and SCFA reduction aggravate acute pancreatitis through classical monocyte activation.","finding":"","journal":"Microbiome","studyType":"Clinical Study"},{"pmid":"39160880","year":"2024","title":"Optimization of a Lethal, Combat-Relevant Model of Sterile Inflammation in Mice for Drug Candidate Screening.","finding":"","journal":"Military medicine","studyType":"Clinical Study"}],"tags":[{"label":"Peptide","category":"modality"},{"label":"Toll-like receptor 4","category":"target"},{"label":"TLR4","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["eritoran tetrasodium","eritoran sodium","eritoran"],"offLabel":[],"synonyms":["eritoran tetrasodium","eritoran sodium","eritoran"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Toll-like receptor 4","targets":[{"gene":"TLR4","source":"DrugCentral","target":"Toll-like receptor 4","protein":"Toll-like receptor 4"}],"modality":"Peptide","explanation":"Think of Toll-like receptor 4 like a security guard that recognizes and responds to potential threats, such as bacteria or viruses. ERITORAN acts like a key that blocks the security guard from sending out an alarm, which can help reduce inflammation and other immune responses. This can be beneficial in treating conditions where the immune system is overactive.","oneSentence":"ERITORAN works by binding to Toll-like receptor 4, a protein involved in the immune response.","technicalDetail":"ERITORAN binds to the extracellular domain of Toll-like receptor 4, preventing the activation of the receptor and subsequent signaling pathways that lead to the production of pro-inflammatory cytokines."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1044","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ERITORAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ERITORAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:01:27.309600","biosimilars":[],"competitors":[{"drugName":"carvedilol","drugSlug":"carvedilol","fdaApproval":"1995-09-14","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"methotrexate","drugSlug":"methotrexate","fdaApproval":"1953-12-07","patentExpiry":"Oct 4, 2026","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"eritoran","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"carvedilol","brandName":"carvedilol","genericName":"carvedilol","approvalYear":"1995","relationship":"same-target"},{"drugId":"methotrexate","brandName":"methotrexate","genericName":"methotrexate","approvalYear":"1953","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":["Community-acquired Pneumonia, Influenza, COVID-19"],"enrollment":20000,"completionDate":"2028-02"},{"nctId":"NCT02267317","phase":"PHASE2","title":"The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2015-01","conditions":["Insulin Sensitivity"],"enrollment":15,"completionDate":"2018-09"},{"nctId":"NCT02321111","phase":"PHASE2","title":"The Role of TLR4 on Lipid-induced Insulin Resistance","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2015-01","conditions":["Insulin Sensitivity"],"enrollment":10,"completionDate":"2018-09"},{"nctId":"NCT00334828","phase":"PHASE3","title":"ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-06","conditions":["Severe Sepsis"],"enrollment":2000,"completionDate":""},{"nctId":"NCT00756912","phase":"PHASE1","title":"A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2008-09","conditions":["Leukemia"],"enrollment":30,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"551541VI0Y","INN_ID":"8562","UMLSCUI":"C1743645","ChEMBL_ID":"CHEMBL501259","KEGG_DRUG":"D04043","DRUGBANK_ID":"DB04933","PDB_CHEM_ID":" E55","PUBCHEM_CID":"6912404","IUPHAR_LIGAND_ID":"4919","SECONDARY_CAS_RN":"185954-98-7","MESH_SUPPLEMENTAL_RECORD_UI":"C512420"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"51.0 hours","clearance":"0.013 mL/min/kg","volumeOfDistribution":"0.048 L/kg"},"publicationCount":98,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41869302","title":"Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.","journal":"Frontiers in immunology"},{"date":"2026 Feb","pmid":"41369124","title":"The Therapeutic Targeting Effect of Toll-Like Receptors and Their Related Signaling Pathways in Cardiomyopathy.","journal":"Immunological investigations"},{"date":"2025 Sep 30","pmid":"41097347","title":"Synthesis and Docking Studies of Glycolipids Inspired by Bacteroides fragilis Lipid A.","journal":"Molecules (Basel, Switzerland)"},{"date":"2025 Mar 24","pmid":"40128912","title":"Dietary emulsifier carboxymethylcellulose-induced gut dysbiosis and SCFA reduction aggravate acute pancreatitis through classical monocyte activation.","journal":"Microbiome"},{"date":"2024 Aug 19","pmid":"39160880","title":"Optimization of a Lethal, Combat-Relevant Model of Sterile Inflammation in Mice for Drug Candidate Screening.","journal":"Military medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ERITORAN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ERITORAN is a small molecule modality targeting Toll-like receptor 4, but its drug class is unknown. Its commercial status is unclear, and it has not been approved by the FDA. The half-life of ERITORAN is approximately 51 hours. Further information on its bioavailability, generic manufacturers, and off-patent status is not available. As a result, its approved indications and safety considerations are also unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}